Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10 - A humanized human leucocyte antigen DR antibody

British Journal of Haematology

Volumn 118, Issue 4, 2002, Pages 959-967

  Stockmeyer, Bernhard ^a   Schiller, Martin ^a   Repp, Roland ^a   Lorenz, Hanns Martin ^a   Kalden, Joachim R ^a   Gramatzki, Martin ^a   Valerius, Thomas ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

ADCC; Apoptosis; G CSF; Hu1D10; Rituxan

Indexed keywords

1D10 ANTIBODY; EPITOPE; GRANULOCYTE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; RITUXIMAB; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; CELL POPULATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; HUMAN; HUMAN CELL; LYMPHOMA; LYMPHOMA CELL; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; APOPTOSIS; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOMA, B-CELL; MICE; RECEPTORS, IGG; T-LYMPHOCYTES, REGULATORY; TUMOR CELLS, CULTURED;

EID: 0036049589     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03722.x     Document Type: Article

References (36)

1. Selective in vivo antitumor effects of monoclonal anti-I-A antibody on B cell lymphoma
2. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
3. Signaling antibodies in cancer therapy
4. Human chimeric IgA antibodies mediate improved effector cell recruitment against B-cell lymphoma
5. The intriguing role of polymorphonuclear neutrophils in antitumor reactions
6. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor
7. Antitumor effects of nonconjugated murine Lym-2 and human-mouse chimeric CLL-1 monoclonal antibodies against various human lymphoma cell lines in vitro and in vivo
8. Synergistic antitumor effects of interleukin-2 and the monoclonal Lym-1 against human Burkitt lymphoma cells in vitro and in vivo
9. Identification and characterization of a new surface membrane antigen found predominantly on malignant B lymphocytes
10. Clinical trials of antibody therapy
11. Preparation of multispecific F(ab′)2 and F(ab′)3 antibody derivates
12. Antigen targeting to myeloid-specific human FcγRI/CD64 triggers enhanced antibody responses in transgenic mice
13. Therapeutic efficacy of FcγRI/CD64-directed bispecific antibodies in B-cell lymphoma
14. Monoclonal antibody therapies - A 'constant' threat to cancer
15. Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use
16. Humanization and characterization of the anti-HLA-DR antibody 1D10
17. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor
18. Phase I study of Hu1D10 monoclonal antibody (Remitogen™) in patients with B-cell lymphoma
19. Suppressing autoimmunity in mice
20. Expression of HLA-DR on neutrophils from patients treated with granulocyte-macrophage colony-stimulating factor for mobilization of stem cells
21. Monoclonal Lym-1 antibody-dependent cytolysis by neutrophils exposed to granulocyte-macrophage colony-stimulating factor: Intervention of FcγRII (CD32), CD11b-CD18 integrins, and CD66b glycoproteins
22. Divergent roles for Fc receptors and complement in vivo
23. Neutrophils express the high affinity receptor for IgG (FcγRI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor
24. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
25. Neutrophils activated by granulocyte-macrophage colony-stimulating factor express receptors for interleukin-3 which mediate class II expression
26. Triggering Fcα receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy
27. Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies
28. Intracellular domains of target antigens influence their capacity to trigger ADCC
29. Monoclonal antibody therapy of B cell lymphoma: Signaling activity on tumor cells appears more important than recruitment of effectors
30. Involvement of the high-affinity receptor for IgG (FcγRI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy
31. FcαRI (CD89) as a novel trigger molecule for bispecific antibody therapy
32. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein
33. Analysis of antigen expression in human malignant tissues: Implications for clinical use of Remitogen™ (Hu1D10)
34. Antibody-targeted immunotherapy for treatment of malignancy
35. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells